How Much Does Mounjaro Cost in Hawaii in 2026?

Brand-Name Mounjaro Retail Pricing Across Hawaii

The wholesale acquisition cost (WAC) set by Eli Lilly for Mounjaro is $1,023 per month, and Hawaii retail pharmacies mirror that figure almost exactly for uninsured or cash-pay patients. That price applies across all dose strengths, from the 2.5 mg starter pen to the 15 mg maximum pen. Unlike mainland metro areas where pharmacy-to-pharmacy competition can shave $10 to $30 off a fill, Hawaii's smaller pharmacy market and island supply-chain logistics leave little room for cash-price negotiation.

A four-pen box covers one month of weekly injections. The FDA-approved prescribing information for Mounjaro specifies titration from 2.5 mg weekly for the first four weeks, then 5 mg weekly, with optional increases in 2.5 mg increments every four weeks up to 15 mg. Because the list price stays flat across strengths, titration does not change your monthly outlay at retail.

Island residents face an additional practical concern: not every pharmacy stocks all dose strengths at all times. Shipment delays between the mainland and Hawaii can create one- to two-week gaps in availability for less common strengths like 12.5 mg or 15 mg. Calling ahead or using a pharmacy that pre-orders your specific dose can prevent missed injections.

For context, tirzepatide's clinical value at these prices is supported by trial data. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% versus 1.86% for semaglutide 1 mg over 40 weeks, establishing its position as one of the most effective GIP/GLP-1 receptor agonists for glycemic control.

Hawaii Medicaid and Mounjaro: What Is Covered

Hawaii Medicaid does not cover Mounjaro for weight loss. The state's Medicaid formulary lists tirzepatide only under its FDA-approved type 2 diabetes indication, and even that coverage requires prior authorization. Prescribers must document failure of or contraindication to metformin and at least one other second-line agent before Medicaid will consider approval.

This gap affects a large segment of the population. According to the Kaiser Family Foundation, roughly 380,000 Hawaii residents (about 26% of the state) are enrolled in Medicaid managed care plans administered through AlohaCare, HMSA, Kaiser, and UnitedHealthcare Community Plan. None of these plans currently include tirzepatide for weight management on their formularies.

If you have type 2 diabetes and meet the prior-authorization criteria, your out-of-pocket cost through Medicaid may be $0 to $3 per fill, depending on your plan. But for obesity without a concurrent diabetes diagnosis, Medicaid is not a pathway to Mounjaro in Hawaii right now.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 or dual GIP/GLP-1 receptor agonists as preferred second-line therapy for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a recommendation that strengthens prior-authorization requests when applicable.

Commercial Insurance Coverage in Hawaii

HMSA, the state's dominant commercial insurer covering over 50% of the privately insured market, includes Mounjaro on its preferred formulary for type 2 diabetes with prior authorization. Kaiser Permanente Hawaii similarly covers tirzepatide for diabetes, though its closed pharmacy system means you must fill at Kaiser facilities. UnitedHealthcare and Aetna plans sold in Hawaii follow their national formulary rules: diabetes coverage with step therapy, weight-loss coverage only through select employer-sponsored plans that have opted into obesity pharmacotherapy benefits.

For commercially insured patients with an approved prior authorization, copays before any discount program typically range from $25 to $150 per month depending on plan design. Patients on high-deductible health plans (HDHPs) may pay full list price ($1,023) until they meet their deductible. That is where the Eli Lilly Mounjaro Savings Card becomes a meaningful tool.

Checking your specific formulary status takes one phone call. Ask your insurer three direct questions: Is tirzepatide on formulary? What tier? What step-therapy requirements apply? The answers determine whether your monthly cost is $25 or $1,023.

Dr. Caroline Messer, an endocrinologist at Lenox Hill Hospital, has noted: "Insurance access to GIP/GLP-1 agonists varies so dramatically by plan that two patients in the same zip code can face a fifty-fold difference in out-of-pocket cost. Checking formulary status before writing the prescription saves everyone time."

The Eli Lilly Mounjaro Savings Card in Hawaii

Eli Lilly's savings card program reduces commercially insured copays to as low as $25 per monthly fill for eligible patients. The card covers up to $150 in copay costs per fill, with a maximum annual benefit that Lilly adjusts periodically. Patients register through Lilly's official program portal with proof of a valid commercial prescription.

Key eligibility rules that affect Hawaii patients:

The card does not work with government insurance. If you carry Medicaid, Medicare, TRICARE, or VA benefits, you are excluded. Hawaii's large military population (over 40,000 active-duty service members and their families use TRICARE) cannot use this card. Patients enrolled in HMSA's QUEST Integration (Medicaid managed care) are also ineligible.

The savings card works at any retail pharmacy that accepts manufacturer copay cards, which includes most CVS, Longs Drugs (CVS-owned), Walgreens, and Times Supermarket pharmacies across the islands. Specialty pharmacies that handle tirzepatide also accept the card.

One common mistake: patients assume the savings card works like a cash-discount coupon for uninsured fills. It does not. You need active commercial insurance with tirzepatide on formulary (even if it requires prior authorization) for the card to activate at the pharmacy counter.

Compounded Tirzepatide in Hawaii: Legality, Cost, and Access

Compounded tirzepatide is legal in Hawaii through 503A-licensed pharmacies. These pharmacies operate under individual patient prescriptions and are regulated by the Hawaii Board of Pharmacy. The average cost for compounded tirzepatide in Hawaii runs approximately $249 per month, roughly 75% less than brand Mounjaro.

The FDA's position on compounding is specific. Tirzepatide appeared on the FDA drug shortage list during 2023 and 2024, which permitted 503A and 503B compounders to produce copies. As of early 2026, the shortage status has been a moving target, and the FDA has issued guidance clarifying enforcement discretion timelines. Patients considering compounded tirzepatide should confirm the current shortage status, because if tirzepatide is fully removed from the shortage list and enforcement discretion periods expire, 503A pharmacies may no longer legally compound it.

Practical differences between compounded and brand tirzepatide that Hawaii patients should understand:

Compounded tirzepatide typically comes as a multi-dose vial requiring the patient to draw up each dose with a syringe, rather than the pre-filled auto-injector pen used for brand Mounjaro. The injection itself is identical (subcutaneous, once weekly), but the preparation step adds complexity. Patients uncomfortable with vial-and-syringe technique may prefer the brand pen.

Purity and potency testing varies by compounder. Reputable 503A pharmacies provide certificates of analysis (COAs) for each batch. Ask for the COA before your first fill. A pharmacy that cannot or will not provide one is a red flag.

Compounded prescriptions are not covered by insurance, so the $249 per month is a true out-of-pocket cost. For uninsured patients paying $1,023 for brand Mounjaro, the savings are $774 per month ($9,288 per year).

Telehealth Prescribing of Mounjaro in Hawaii

Hawaii permits telehealth prescribing of Mounjaro with no in-person visit requirement for the initial consultation. The state's telehealth parity law, updated in 2021, requires insurers to cover telehealth visits the same way they cover in-person visits, which means your copay for a virtual prescriber appointment should match your standard office-visit copay.

Several national telehealth platforms that prescribe tirzepatide operate in Hawaii, including HealthRX. The typical workflow: complete a medical intake, have a synchronous video visit with a licensed prescriber, receive your prescription electronically, and fill at a local pharmacy or through mail-order.

For patients on neighbor islands (Maui, Kauai, Big Island, Molokai, Lanai), telehealth removes a significant access barrier. Endocrinology and obesity-medicine specialists are concentrated on Oahu, and a telehealth visit eliminates the cost and time of inter-island flights.

One regulatory detail matters: the prescribing clinician must hold an active Hawaii medical license or be registered through an interstate compact. Verify that your telehealth provider's clinicians are Hawaii-licensed before your appointment to avoid prescription fulfillment issues at local pharmacies.

Strategies to Lower Your Mounjaro Cost in Hawaii

The lowest-cost pathway depends on your insurance status. Here is how the math breaks down for each scenario.

Commercially insured with formulary coverage: Use the Eli Lilly savings card. Expected monthly cost: $25 to $50. This is the cheapest legal option available in Hawaii for patients who qualify.

Commercially insured without formulary coverage: File a formulary exception request through your prescriber. If denied, appeal. While waiting, compounded tirzepatide at $249 per month is the most practical bridge. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity supports the use of GIP/GLP-1 receptor agonists for patients with BMI ≥30 (or ≥27 with comorbidities), which strengthens exception requests.

Uninsured: Compounded tirzepatide at $249 per month is the most cost-effective option. Alternatively, Eli Lilly's patient assistance program provides brand Mounjaro at no cost for patients who meet income thresholds (generally <400% of the federal poverty level).

Medicare or TRICARE: Neither the savings card nor most formulary pathways cover weight-loss use. Compounded tirzepatide (if legally available) or Lilly's patient assistance program are the primary options. Medicare Part D covers Mounjaro for type 2 diabetes at tier 3 or tier 4 copays, typically $100 to $300 per month before catastrophic coverage kicks in.

A 2024 analysis published in JAMA Network Open found that out-of-pocket costs exceeding $50 per month reduced GLP-1 RA adherence by 32% over 12 months, a finding that underscores why chasing the lowest available price is not just a financial exercise but a clinical one.

Clinical Efficacy: What You Get for the Cost

Tirzepatide's dual GIP/GLP-1 mechanism separates it from semaglutide (Ozempic, Wegovy) and other single-incretin drugs. The SURPASS-2 trial compared tirzepatide head-to-head against semaglutide 1 mg in 1,879 adults with type 2 diabetes. At 40 weeks, tirzepatide 15 mg achieved a 2.58% HbA1c reduction versus 1.86% for semaglutide, with 86% of tirzepatide patients reaching HbA1c <7% compared to 79% for semaglutide.

Weight loss data reinforced the separation. Tirzepatide 15 mg produced 12.4 kg mean weight loss versus 6.2 kg for semaglutide 1 mg in that same trial. The SURMOUNT-1 trial (N=2,539), published in the New England Journal of Medicine, tested tirzepatide specifically for obesity in adults without diabetes and recorded 22.5% mean body weight reduction at 72 weeks with the 15 mg dose, compared to 2.4% with placebo.

Dr. Ania Jastreboff, the lead investigator of SURMOUNT-1 at Yale School of Medicine, stated: "The magnitude of weight reduction observed with tirzepatide is unprecedented among approved pharmacotherapies for obesity and approaches the range historically seen only with bariatric surgery."

These numbers matter when evaluating cost-effectiveness. A patient spending $249 per month on compounded tirzepatide ($2,988 per year) who achieves 15 to 20% body weight loss may avoid or delay bariatric surgery ($20,000 to $35,000), reduce antihypertensive medications, or achieve type 2 diabetes remission. The SURMOUNT-4 trial showed that discontinuing tirzepatide after 36 weeks led to regain of approximately two-thirds of the lost weight by 88 weeks, which means continued treatment is the clinical expectation, not a short course.

Hawaii-Specific Pharmacy and Supply Chain Considerations

Hawaii's geographic isolation creates supply-chain dynamics that mainland patients do not face. All brand Mounjaro inventory arrives via container ship or air freight from mainland distribution centers. During peak-demand periods, pharmacies on neighbor islands (particularly Molokai and Lanai) may experience stockouts lasting one to three weeks.

Three practical steps reduce the risk of a missed dose:

First, establish a relationship with one pharmacy rather than shopping around. Pharmacies that can predict your refill schedule will pre-order your dose strength. Second, consider mail-order pharmacy through your insurer or through a telehealth platform that ships direct. Mail-order shipments are dispatched from mainland fulfillment centers and typically arrive in Hawaii within three to five business days. Third, keep a two-week buffer by refilling at the 21-day mark rather than waiting until day 28.

For compounded tirzepatide, most 503A pharmacies fulfilling Hawaii prescriptions are mainland-based and ship cold-chain via overnight or two-day express. Verify that your compounder uses validated cold-chain packaging, because tirzepatide degrades above recommended storage temperatures and Hawaii's ambient heat during ground transport can compromise the product.

Comparing Mounjaro to Alternatives Available in Hawaii

Tirzepatide is not the only GLP-1-class option available in Hawaii. Semaglutide (Wegovy for obesity, Ozempic for diabetes) lists at approximately $1,349 per month, higher than Mounjaro's $1,023. Compounded semaglutide, where legally available, runs $150 to $350 per month depending on dose. Liraglutide (Saxenda) lists at roughly $1,400 per month and requires daily injections rather than weekly, which makes it less convenient and more expensive per month.

On a cost-per-percentage-of-body-weight-lost basis, tirzepatide outperforms its competitors. The SURMOUNT-1 data showed 22.5% weight loss with tirzepatide 15 mg at 72 weeks. The STEP-1 trial (N=1,961), published in the New England Journal of Medicine, showed 14.9% weight loss with semaglutide 2.4 mg at 68 weeks. At $249 per month compounded, tirzepatide costs approximately $11 per month per percentage point of body weight lost, versus $15 to $24 for compounded semaglutide depending on dose and source.

The choice between tirzepatide and semaglutide should be clinical first, financial second. Patients with type 2 diabetes may benefit more from tirzepatide's dual-incretin mechanism and superior HbA1c reduction. Patients without diabetes whose primary goal is weight management have strong evidence supporting either drug, and cost or insurance coverage may reasonably tip the decision.